Stem cell treatments for neurodegenerative diseases are expected to reach clinical trials soon.  One major task en route to the clinic is to generate standardized good manufacturing practice (GMP)-grade human-pluripotent stem cell derived neural-progenitors which will mature and function in the adult brain after transplantation.  However, it remains a challenge for researchers to control stem cells accurately in the lab in order to achieve successful … Continue reading Breakthrough in the production of dopamine neurons for Parkinson’s disease.